Bulletin
Investor Alert

Harrow Health Inc.

NAS: HROW

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Harrow Health Inc.

After Hours

 --Quotes are delayed by 20 min

Feb 3, 2023, 4:16 p.m.

HROW
/zigman2/quotes/206805265/composite

$

17.50

Change

0.00 0.00%

Volume

Volume 41,282

Quotes are delayed by 20 min

/zigman2/quotes/206805265/composite

Today's close

$ 16.16

$ 17.50

Change

+1.34 +8.29%

Day low

Day high

$15.99

$17.84

Open

52 week low

52 week high

$5.40

$17.84

Open

Company Description

Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development.The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The comp...

Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development.The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

Valuation

Price to Sales Ratio

3.19

Price to Book Ratio

20.60

Price to Cash Flow Ratio

45.49

Enterprise Value to EBITDA

113.11

Enterprise Value to Sales

5.32

Efficiency

Total Asset Turnover

0.93

Liquidity

Current Ratio

6.24

Quick Ratio

5.81

Cash Ratio

5.21

Profitability

Gross Margin

74.87

Operating Margin

2.43

Pretax Margin

-24.80

Net Margin

-24.85

Return on Assets

-23.12

Return on Equity

-93.62

Return on Total Capital

2.53

Capital Structure

Total Debt to Total Assets

79.28

Officers and Executives

Name Age Officer Since Title
Mr. Mark L. Baum 48 2006 Chairman & Chief Executive Officer
Mr. Andrew R. Boll 37 2011 Chief Financial Officer & Secretary
Dr. Larry M. Dillaha 57 - Chief Medical Officer
Mr. Andrew Livingston - - Chief Innovation Officer
Mr. John P. Saharek 60 2012 Vice President-Commercialization

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
01/02/2023 Mark L. Baum
Chief Executive Officer; Director 		35,179   Derivative/Non-derivative trans. at $14.76 per share. 519,242
01/02/2023 Andrew R. Boll
Chief Financial Officer 		9,602   Derivative/Non-derivative trans. at $14.76 per share. 141,725
01/02/2023 Mark L. Baum
Chief Executive Officer; Director 		88,000   Derivative/Non-derivative trans. at $0 per share. 0
01/02/2023 Andrew R. Boll
Chief Financial Officer 		23,000   Derivative/Non-derivative trans. at $0 per share. 0
12/22/2022 Mark L. Baum
Chief Executive Officer; Director 		25,000   Acquisition at $13.39 per share. 334,750
12/22/2022 Andrew R. Boll
Chief Financial Officer 		2,500   Acquisition at $13.54 per share. 33,850
12/22/2022 R. Lawrence van Horn
Director 		1,860   Acquisition at $13.42 per share. 24,961
12/21/2022 Martin A. Makary
Director 		25,000   Acquisition at $13.37 per share. 334,250
12/14/2022 Opaleye Management, Inc.
16,183   Acquisition at $10.52 per share. 170,245
12/14/2022 Opaleye Management, Inc.
415,000   Acquisition at $10.52 per share. 4,365,800
09/30/2022 Richard L. Lindstrom
Director 		40,000   Disposition at $12.62 per share. 504,800
09/28/2022 Opaleye Management, Inc.
1,085   Acquisition at $9.77 per share. 10,600
09/28/2022 Opaleye Management, Inc.
10,000   Acquisition at $9.77 per share. 97,700
04/13/2022 Opaleye Management, Inc.
2,832   Acquisition at $6.76 per share. 19,144
04/13/2022 Opaleye Management, Inc.
10,000   Acquisition at $6.76 per share. 67,600
04/12/2022 Opaleye Management, Inc.
3,557   Acquisition at $6.75 per share. 24,009
04/12/2022 Opaleye Management, Inc.
25,000   Acquisition at $6.75 per share. 168,750
02/19/2022 Andrew R. Boll
Chief Financial Officer 		20,605   Derivative/Non-derivative trans. at $7.87 per share. 162,161
02/19/2022 John P. Saharek
President, ImprimisRx 		25,923   Derivative/Non-derivative trans. at $7.87 per share. 204,014
02/19/2022 Andrew R. Boll
Chief Financial Officer 		50,000   Derivative/Non-derivative trans. at $0 per share. 0
02/19/2022 John P. Saharek
President, ImprimisRx 		50,000   Derivative/Non-derivative trans. at $0 per share. 0
01/28/2022 Opaleye Management, Inc.
1,343   Acquisition at $6.89 per share. 9,253
01/28/2022 Opaleye Management, Inc.
5,000   Acquisition at $6.89 per share. 34,450
/news/latest/company/us/hrow

MarketWatch News on HROW

  1. Imprimis Pharma initiated as buy at B Riley FBR

    2:11 p.m. Dec. 13, 2018

    - Ciara Linnane

  2. Express Scripts opts for $1 alternative to Turing’s $750 Daraprim

    5:56 a.m. Dec. 1, 2015

    - Jonathan D. Rockoff

  4. Duckburg Economics: Pricing and Scarcity in Drugs

    11:44 p.m. Oct. 30, 2015

    - Barron's Online

/news/nonmarketwatch/company/us/hrow

Other News on HROW

  1. Harrow Health, Inc. (HROW) Q3 2022 Earnings Call Transcript

    8:49 p.m. Nov. 14, 2022

    - Seeking Alpha

  2. 10-Q: HARROW HEALTH, INC.

    5:20 p.m. Nov. 14, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  7. LHC Group (LHCG) Q3 Earnings and Revenues Lag Estimates

    5:05 p.m. Nov. 2, 2022

    - Zacks.com

  9. Harrow Health gains as subsidiary launches topical antibiotic

    2:19 p.m. Sept. 29, 2022

    - Seeking Alpha

  11. SA Interview: Value Investing With Michigan Value Investor

    6:30 a.m. Aug. 20, 2022

    - Seeking Alpha

  13. SRK Capital H1 2022 Investor Letter

    10:00 p.m. Aug. 18, 2022

    - Seeking Alpha

  14. Private Capital Buys 4, Sells 1 in 2nd Quarter

    4:00 p.m. Aug. 15, 2022

    - GuruFocus.com

  16. 10-Q: HARROW HEALTH, INC.

    3:46 p.m. Aug. 9, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  17. Harrow Health files for $300M mixed shelf offering

    4:44 p.m. May 26, 2022

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Harrow Health, Inc.

102 Woodmont Boulevard

Suite 610

Nashville, Tennessee 37205

Phone

1 6157334730

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

View SEC Filings

Revenue

$72.48M

Net Income

$-18.01M

Employees

182.00

Annual Report for HROW

/news/pressrelease/company/us/hrow

Press Releases on HROW

  3. Friday 12/23 Insider Buying Report: COIN, HROW

    1:52 p.m. Dec. 23, 2022

    - MarketNewsVideo.com

  5. Harrow Secures Capital to Close Recently Announced Acquisition

    7:00 a.m. Dec. 16, 2022

    - BusinessWire - BZX

  7. Harrow Prices $25 Million Offering

    6:31 a.m. Dec. 14, 2022

    - BusinessWire - BZX

  9. Harrow and iOR Partners Expand National Product Supply Agreement

    8:00 a.m. Nov. 30, 2022

    - BusinessWire - BZX

  10. Harrow Announces Third Quarter 2022 Financial Results

    4:05 p.m. Nov. 14, 2022

    - BusinessWire - BZX

  11. Harrow Launches Atropine.com

    8:00 a.m. Nov. 10, 2022

    - BusinessWire - BZX

  14. Harrow Sells Non-Ophthalmic Compounding Business

    4:35 p.m. Oct. 5, 2022

    - BusinessWire - BZX

  19. Harrow Health Announces Second Quarter 2022 Financial Results

    3:01 p.m. Aug. 9, 2022

    - BusinessWire - BZX

  21. Loading more headlines...
Link to MarketWatch's Slice.